头颈癌放疗与系统治疗整合:专家意见与共识路线图
国际多学科专家组针对局部晚期和复发/转移性头颈鳞癌及鼻咽癌四个临床场景,用加权Borda计数法对预设议题排序,识别出八个优先研究方向,并提出理想临床试验设计以弥补放疗与系统治疗整合中的证据缺口。
要点
- 局部晚期头颈鳞癌优先方向为诊断时风险适配预后评估及围手术期免疫治疗后个体化化放疗。
- 复发/转移性头颈鳞癌聚焦一线治疗中新发转移的区域放疗角色及寡转移PD-L1 CPS阳性病的治疗顺序。
- 局部晚期鼻咽癌优先研究强化策略的患者选择及诱导化疗免疫治疗后降阶治疗的患者选择。
核心结论
- 本研究明确了头颈癌放疗与系统治疗整合中的关键知识缺口,并为未来国际共识制定和临床研究提供路线图以推进个体化治疗策略。
研究设计与样本
- 国际放疗、临床肿瘤学和内科肿瘤学多学科专家组识别未满足需求优先领域,评估四个临床场景:局部晚期头颈鳞癌、复发/转移性头颈鳞癌、局部晚期鼻咽癌和复发/转移性鼻咽癌。
- 专家使用加权Borda计数法对预设议题短名单排序,并提出理想临床试验设计以解决识别的未满足需求。
主要发现
- 十五份专家回复在四个场景中识别出八个优先议题。
- 局部晚期头颈鳞癌首要议题包括诊断时风险适配预后评估和围手术期免疫治疗后个体化化放疗。
- 复发/转移性头颈鳞癌专家强调一线治疗中新发转移病的区域放疗作用以及寡转移PD-L1 CPS阳性病的治疗顺序为关键需求。
- 局部晚期鼻咽癌首要议题为强化策略的患者选择和诱导化疗免疫治疗后降阶治疗的患者选择。
- 复发/转移性鼻咽癌专家优先考虑一线治疗获益的新发寡转移病患者中区域放疗与转移导向治疗的顺序。
临床怎么用
- 专家意见提示局部晚期头颈鳞癌应重视诊断时风险适配预后评估并探索围手术期免疫治疗后个体化化放疗。
- 复发/转移性头颈鳞癌一线治疗中可考虑区域放疗用于新发转移病,寡转移PD-L1 CPS阳性病需关注治疗顺序。
- 局部晚期鼻咽癌应研究强化和降阶策略的患者选择,尤其诱导化疗免疫治疗后降阶治疗的患者选择。
- 复发/转移性鼻咽癌一线治疗获益的新发寡转移病患者需明确区域放疗与转移导向治疗的顺序。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Integration of radiation therapy (RT) with systemic treatments in head and neck cancers has transformed therapeutic paradigms, yet optimal combinations remain undefined. This study aimed to identify priority areas of unmet need in combining RT with systemic treatment in both squamous cell carcinoma of the head and neck (SCCHN) and nasopharyngeal cancer (NPC). METHODS: A multidisciplinary panel of international experts in radiation, clinical, and medical oncology convened to identify priority areas of unmet need. Four clinical scenarios were evaluated: locally-advanced (LA) SCCHN; recurrent/metastatic (R/M) SCCHN; LA NPC; and R/M NPC. Experts ranked a predefined shortlist of topics using weighted Borda count methodology and proposed ideal clinical trial designs to address the identified unmet needs. RESULTS: Fifteen expert responses identified eight priority topics across the four scenarios. In locally-advanced SCCHN, top priorities included risk-adapted prognostic evaluation at diagnosis and personalized chemoradiation following peri-operative immunotherapy. For R/M SCCHN, experts highlighted the role of locoregional radiation in de-novo metastatic disease on first-line therapy and treatment sequencing in oligometastatic programmed death ligand-1 (PD-L1) combined positive score (CPS)-positive disease as the key need. In LA NPC, the leading topics were patient selection for intensification strategies and for de-escalation after induction chemo-immunotherapy. In R/M NPC, experts prioritized sequencing locoregional RT and metastasis-directed therapy in patients with de-novo oligometastatic disease who are benefiting from first-line treament. CONCLUSIONS: This study defines critical knowledge gaps in integrating RT with systemic treatments in head and neck cancer, and provides a roadmap for future international consensus development and clinical research to advance personalized treatment strategies.
引用
- Becherini C, Banini M, Blanchard P, et al. Integration of radiation therapy with systemic treatments in head and neck cancer: expert opinion and roadmap to consensus. Radiother Oncol. 2026. PMID: 42520977. doi:10.1016/j.radonc.2026.111711
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。